The prevalence of Helicobacter pylori and its effect on prognosis of patients with COVID-19 Helicobacter pylori and COVID-19

Main Article Content

Ahmed Bilal Genc
Selcuk Yaylaci
Hamad Dheir
Didar Senocak
Elif Ozozen
Kubilay Issever
Deniz Cekic
Havva Kocayigit
Cengiz Karacaer
Elif Kose
Ahmet Nalbant
Ali Tamer
Mehmet Koroglu
Oguz Karabay

Abstract

Objective: SARS-CoV-2 RNA positivity in stool in COVID-19 infection has been reported at rates varying between 6-83%. The purpose of this study was to determine the prevalence of H.pylori and investigate whether it determines the disease prognosis in COVID-19 patients.


Methods: This study was conducted on 117 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia and tested for stool H.pylori antigen. Stool H. pylori test outcomes, demographic parameters, laboratory findings, and prognostic predictors of disease were recorded. The effect of the presence of H.pylori in patients with COVID-19 was analyzed.


Results: The mean age of 117 included patients was 49.68 ± 14.62 years, 78 (66.7%) had COVID PCR positivity and 32 (27.35%) had H.pylori positivity. There was no statistical difference in demographic data, prognosis, and laboratory parameters between those with and without H.pylori.


Conclusion: H.pylori positivity was detected as 27.35% in patients with COVID-19 infection. However, we could not find the positive or negative effect of H.pylori on the prognosis of COVID-19 disease. In conclusion, according to the results of this study, H. pylori positivity or negativity neither determined the severity of the COVID-19 disease nor the poor prognostic indicators of the disease.

Downloads

Download data is not yet available.

Article Details

How to Cite
Genc, A. B., Yaylaci, S., Dheir, H., Senocak, D., Ozozen, E., Issever, K., Cekic, D., Kocayigit, H., Karacaer, C., Kose, E., Nalbant, A., Tamer, A., Koroglu, M., & Karabay, O. (2021). The prevalence of Helicobacter pylori and its effect on prognosis of patients with COVID-19. Medical Science and Discovery, 8(4), 208-212. https://doi.org/10.36472/msd.v8i4.509
Section
Research Article

References

1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA: the journal of the American Medical Association [Internet] 2020;Available from: http://dx.doi.org/10.1001/jama.2020.1097

2. Li Y, Hu Y, Yu Y et al. Positive result of Sars-Cov-2 in faeces and sputum from discharged patients with COVID-19 in Yiwu, China. Journal of medical virology [Internet] 2020;Available from: http://dx.doi.org/10.1002/jmv.25905

3. Guan W-J, Ni Z-Y, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine 2020; 382: 1708.

4. Szymczak WA, Yitzchak Goldstein D, Orner EP et al. Utility of Stool PCR for the Diagnosis of COVID-19: Comparison of Two Commercial Platforms [Internet]. Journal of Clinical Microbiology2020; 58. Available from: http://dx.doi.org/10.1128/jcm.01369-20

5. Mesoraca A, Margiotti K, Viola A, Cima A, Sparacino D, Giorlandino C. Evaluation of SARS-CoV-2 viral RNA in fecal samples. Virology journal 2020; 17: 86.

6. van Doorn AS, Meijer B, Frampton CMA, Barclay ML, de Boer NKH. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Alimentary pharmacology & therapeutics [Internet] 2020;Available from: http://dx.doi.org/10.1111/apt.16036

7. Parasa S, Desai M, Thoguluva Chandrasekar V et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA network open 2020; 3: e2011335.

8. Tariq R, Saha S, Furqan F, Hassett L, Pardi D, Khanna S. Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clinic proceedings. Mayo Clinic 2020; 95: 1632.

9. Hooi JKY, Lai WY, Ng WK et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153: 420.

10. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020; 368: m1198.

11. Sarfo FS, Eberhardt KA, Dompreh A et al. Helicobacter pylori Infection Is Associated with Higher CD4 T Cell Counts and Lower HIV-1 Viral Loads in ART-Naïve HIV-Positive Patients in Ghana. PloS one 2015; 10: e0143388.







12. Nevin DT, Morgan CJ, Graham DY, Genta RM. Helicobacter pylori gastritis in HIV-infected patients: a review. Helicobacter 2014; 19: 323.

13. Nkuize M, De Wit S, Muls V et al. HIV-Helicobacter pylori Co-Infection: Antibiotic Resistance, Prevalence, and Risk Factors. PloS one 2015; 10: e0145119.

14. Okuda M, Osaki T, Kikuchi S et al. Evaluation of a stool antigen test using a mAb for native catalase for diagnosis of Helicobacter pylori infection in children and adults. Journal of medical microbiology 2014; 63: 1621.

15. Makristathis A, Barousch W, Pasching E et al. Two Enzyme Immunoassays and PCR for Detection ofHelicobacter pylori in Stool Specimens from Pediatric Patients before and after Eradication Therapy [Internet]. Journal of Clinical Microbiology2000; 38: 3710. Available from: http://dx.doi.org/10.1128/jcm.38.10.3710-3714.2000

16. Erzin Y, Altun S, Dobrucali A et al. Comparison of two different stool antigen tests for the primary diagnosis of Helicobacter pylori infection in turkish patients with dyspepsia. Helicobacter 2004; 9: 657.

17. Ford AC, Axon ATR. Epidemiology of Helicobacter pylori infection and Public Health Implications [Internet]. Helicobacter2010; 15: 1. Available from: http://dx.doi.org/10.1111/j.1523-5378.2010.00779.x

18. Demir T, Turan M, Tekin A. Kırşehir bölgesindeki dispeptik hastalarda Helicobacter pylori antijen prevalansı, Dicle Tıp Derg 2011;38(1):44-8).

19. Wang J, Chen R-C, Zheng Y-X et al. Helicobacter pylori infection may increase the risk of progression of chronic hepatitis B disease among the Chinese population: a meta-analysis. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2016; 50: 30.

20. Wang M-Y, Yue J-Y, Zhang Y-X, Liu X-D, Gao X-Z. Helicobacter pylori infection in asymptomatic HBV carriers, alcohol users and normal adult population in Shandong Province, China. Clinics and research in hepatology and gastroenterology 2011; 35: 560.

21. Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of Helicobacter pylori: a concise review. World journal of gastroenterology: WJG 2014; 20: 11950.

22. Alarcón T, Llorca L, Perez-Perez G. Impact of the Microbiota and Gastric Disease Development by Helicobacter pylori. Current topics in microbiology and immunology 2017; 400: 253.

23. Eberhardt KA, Sarfo FS, Dompreh A et al. Helicobacter pylori Coinfection Is Associated With Decreased Markers of Immune Activation in ART-Naive HIV-Positive and in HIV-Negative Individuals in Ghana. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2015; 61: 1615.

24. Alzahrani S, Lina TT, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Effect of Helicobacter pylori on gastric epithelial cells. World journal of gastroenterology: WJG 2014; 20: 12767.

25. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical chemistry and laboratory medicine: CCLM / FESCC 2020; 58: 1021.